test

David Kim

@Paradigm Biocapital Advisors Lp

Latest period2024 - Q3ReportedManaged Assets$2.956BTotal holdings31
Assets growth rate13.13%Assets growth rate (2-Q avg)2.56%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Paradigm Biocapital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 31 positions.

Assets under management

The assets under management (AUM) of Paradigm Biocapital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.956B in assets, with a quarterly growth rate of 13.13% and a 2-quarter average growth rate of 2.56%. The portfolio is managed by David Kim, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
EWTXEdgewise Therapeutics Inc
Recent Activity
Increased 19.95%
2.52%
$74.443M
2.789M shares@ $26.7 avg price
IRONDisc Medicine Inc
Recent Activity
Decreased -44.62%
2.49%
$73.598M
1.498M shares@ $49.15 avg price
VRDNViridian Therapeutics Inc
Recent Activity
Decreased -0.02%
2.23%
$65.877M
2.896M shares@ $22.76 avg price
OLMAOlema Pharmaceuticals Inc
Recent Activity
Decreased -30.36%
2.23%
$65.713M
5.504M shares@ $11.94 avg price
ARVNArvinas Inc
Recent Activity
Decreased -4.02%
1.95%
$57.633M
2.34M shares@ $24.63 avg price
YMABY-mabs Therapeutics Inc
Recent Activity
Increased 5.58%
1.82%
$53.735M
4.086M shares@ $13.16 avg price
COGTCogent Biosciences Inc
Recent Activity
Increased 27.19%
1.69%
$49.785M
4.61M shares@ $10.81 avg price
VERAVera Therapeutics Inc
Recent Activity
New Position
1.65%
$48.481M
1.097M shares@ $44.2 avg price
MLTXMoonlake Immunotherapeutics
Recent Activity
New Position
1.59%
$46.965M
931,480 shares@ $50.43 avg price
BGNEBeigene Ltd
Recent Activity
New Position
1.53%
$44.977M
200,336 shares@ $224.51 avg price